Provided by Tiger Trade Technology Pte. Ltd.

HENLIUS

65.300
-0.150-0.23%
Volume:428.70K
Turnover:27.89M
Market Cap:35.49B
PE:39.27
High:66.900
Open:65.550
Low:64.300
Close:65.450
52wk High:92.000
52wk Low:15.200
Shares:543.49M
HK Float Shares:163.43M
Volume Ratio:0.59
T/O Rate:0.26%
Dividend:- -
Dividend Rate:- -
EPS(LYR):1.663
ROE:27.54%
ROA:4.97%
PB:9.45
PE(LYR):39.27
PS:5.56

Loading ...

HENLIUS (02696): Phase 2/3 Clinical Trial Applications for HLX22 Combined with HLX87 in HER2-Positive Breast Cancer First-Line Treatment and Neoadjuvant Therapy Approved by NMPA

Stock News
·
1 hour ago

Shanghai Henlius Biotech Secures NMPA Approval for Phase 2/3 Trials of HLX22 and HLX87 in HER2-Positive Breast Cancer

Reuters
·
1 hour ago

Shanghai Henlius Biotech Inc - Nmpa Approves Phase 2/3 Trials for Hlx22 and Hlx87

THOMSON REUTERS
·
1 hour ago

Henlius Biotech's Breast Cancer Drug Included in China's Reimbursement Drug List

MT Newswires Live
·
Yesterday

HENLIUS (02696): FULINNING® (Fulvestrant Citrate Capsules) Included in China's National Reimbursement Drug List

Stock News
·
Dec 07

Shanghai Henlius Biotech's FUTUONING Added to China's National Reimbursement Drug List

Reuters
·
Dec 07

Shanghai Henlius (2696) Announces 2025 Fourth EGM and Seeks Approval for Sinopharm Distribution Framework Agreement

Bulletin Express
·
Dec 03

Shanghai Henlius Biotech (2696) Announces EGM and Proposes New Distribution Framework with Sinopharm Group

Bulletin Express
·
Dec 03

Shanghai Henlius Biotech Inc. Announces Date for 2025 Fourth Extraordinary General Meeting

Reuters
·
Dec 03

Shanghai Henlius (2696) Announces Renewal of Sinopharm Distribution Collaboration

Bulletin Express
·
Dec 03

Shareholders to Vote on Renewal of Sinopharm Distribution Collaboration at Shanghai Henlius Biotech Inc. EGM

Reuters
·
Dec 03

HENLIUS (02696) Enters Cooperation Agreement with Auven Pharma for Commercialization of Fovistinib Citrate Capsules

Stock News
·
Dec 03

Shanghai Henlius Biotech 9M Revenue RMB 1,693 Million

THOMSON REUTERS
·
Dec 03

Shanghai Henlius Biotech Inc - Jinzhou Avanc Pharmaceutical to Grant Exclusive License to Commercialise Fovinaciclib Citrate Capsules

THOMSON REUTERS
·
Dec 03

Shanghai Henlius Biotech Partners with Avanc Pharma for Fovinaciclib Citrate Capsules

Reuters
·
Dec 03

10th Zhitong Capital Market Annual Conference Honors Excellence with 25 Awards Unveiled

Stock News
·
Dec 03

Henlius Biotech's Osteoporosis Drug Application Accepted in China

MT Newswires Live
·
Dec 02

HENLIUS (02696): NMPA Accepts Marketing Application for Denosumab Biosimilar HLX14

Stock News
·
Dec 02

Shanghai Henlius Biotech Inc - Nda for Biosimilar of Denosumab Hlx14 (Recombinant Anti-Rankl Human Monoclonal- Antibody Injection) Accepted by Nmpa

THOMSON REUTERS
·
Dec 02

Shanghai Henlius Biotech NDA for Denosumab Biosimilar Accepted by China NMPA

Reuters
·
Dec 02